Adial Pharmaceuticals, Inc. (ADIL) NASDAQ
2.36
-0.09(-3.67%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.36
-0.09(-3.67%)
Currency In USD
| Previous Close | 2.45 |
| Open | 2.46 |
| Day High | 2.46 |
| Day Low | 2.34 |
| 52-Week High | 19 |
| 52-Week Low | 1.31 |
| Volume | 21,898 |
| Average Volume | 128,930 |
| Market Cap | 2.26M |
| PE | -0.48 |
| EPS | -4.89 |
| Moving Average 50 Days | 1.74 |
| Moving Average 200 Days | 5.48 |
| Change | -0.09 |
Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update
GlobeNewswire Inc.
Mar 06, 2026 1:00 PM GMT
GLEN ALLEN, Va., March 06, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and
Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement
GlobeNewswire Inc.
Mar 03, 2026 1:17 PM GMT
The Collaboration Framework marks Adial’s first step towards commercial partnership and establishing an exclusive European pathway as AD04 advances toward pivotal Phase 3 developmentGLEN ALLEN, Va., March 03, 2026 (GLOBE NEWSWIRE) -- Adial Pharmace
Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement
GlobeNewswire Inc.
Feb 24, 2026 2:00 PM GMT
Company Highlights Advanced Partnering Discussions as AD04 Advances Toward Phase 3GLEN ALLEN, Va., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company f